Question · asked by 1 review
rHuEPO once/week vs rHuEPO: Adverse effects: access problems
What each review found
Current versions only| Finding | Effect | Studies | GRADE certainty |
|---|---|---|---|
rHuEPO once/week vs rHuEPO 2 to 3 times/week Adverse effects: access problems · patients with the anaemia of end‐stage kidney disease undergoing dialysis Frequency of administration of erythropoiesis‐stimulating agents for the anaemia of end‐stage kidney disease… (2014) · Cochrane Headline outcomes only | no estimate extracted | 1 study · 173 participants | GRADE not reported |
Findings are shown side by side, never pooled across reviews.
The reviews
| Review | Searched up to | Included studies | AMSTAR 2 |
|---|---|---|---|
| Frequency of administration of erythropoiesis‐stimulating agents for the anaemia of end‐stage kidney disease in dialysis patients 2014 · Cochrane Headline outcomes only | Not reported | list not extracted yet | Not assessed |
Studies behind the findings
None of these reviews ties its included studies to this outcome in the data here. Cochrane reviews and reviews with headline outcomes only do not list their studies yet.
How reviews are matched to this question
Reviews word the same question differently. Four decision models (TypeSafe's Jev, Liquid AI's d1-ultra, SubQ Snap and Baseten's Elephant) judged each wording of the population, intervention, comparator and outcome against the others; two wordings count as the same when at least three of them agree and none clearly disagrees, and findings count as this question only when all four elements match. Timing, setting and subgroup never split a question: they are shown on each finding.